About 85% of women and 30% of men will experience hormonal challenges in their lifetime. Recognizing this, The HRT Club is stepping up by providing consumers access to hormone replacement therapies, treatments that replace lost hormones and are commonly used for menopause.
The Bridgewater, New Jersey-based company announced the commercial release of its solution last week following an April soft launch. Members pay $99 a year and gain access to a network of over 700 healthcare providers that partner with The HRT Club and can prescribe hormone treatments. Members don’t require insurance for the company’s services.
The HRT Club bypasses pharmacy benefit managers and has direct agreements with drug manufacturers and independent wholesalers, allowing them to provide patients with discounts on prescribed treatment options. These treatments include estrogen therapies, progesterone therapies, testosterone therapies and sexual health treatments. For some medications, members can receive up to 90% in savings, the company claimed.
Improving the Healthcare Financial Experience to Help Care Flow
Zelis CEO Amanda Eisel shares her perspective on how the company is solving the problems of a fragmented health financial system to benefit all.
“We created The HRT Club to address a pressing public health crisis: two out of three Americans with hormone deficiencies cannot access the medications they need. The root of the problem lies with middlemen — pharmacy benefit managers and wholesalers — who inflate prices and restrict access,” said Cyrille Labourel, CEO of The HRT Club, in an email. “As a result, hormone replacement therapy (HRT) treatments in the U.S. cost, on average, five times more than in other countries. The HRT Club is here to change that.”
Labourel isn’t the only one who has a bone to pick with PBMs. The pharmacy middlemen — specifically CVS Caremark, Optum Rx and Express Scripts — have come under fire recently from legislators and the Federal Trade Commission. The latter has released two reports on PBMs, which declare that the market has become too concentrated and that PBMs hike up the cost of life-saving drugs. Several other companies are cutting out PBMs in order to make prescriptions cheaper, including Mark Cuban Cost Plus Drug Company and DiRx, though these companies don’t focus on HRT medications.
The HRT Club already has more than 3,000 members across 42 states. About 90% of its customers are women, though more men are seeking testosterone replacement therapy, and the company has a growing population of patients undergoing gender transition, according to Labourel. The HRT Club is backed by a $10 million investment from its parent company Besins Healthcare, a manufacturer of HRT products.
In 2025, The HRT Club hopes to reach 50,000 members nationwide, the announcement stated. In addition, it aims to expand to other hormonal therapies in the future, such as GLP-1 medications. It also plans to create tech solutions for prescription tracking and refills, as well as a community platform for members to share their experiences.
What Keeps Healthcare CIOs Up at Night: Balancing Technology Investments with Consumer Expectations
When it comes to managing inbound phone calls, underperformance has devastating cost implications.
“We aim to be the go-to destination for hormonal health, driven by our mission to democratize access to hormone treatments,” Labourel said. “Our focus extends beyond sex hormones; our ultimate goal is to redefine the healthcare model — putting patients first by bypassing the traditional insurance, PBM, and wholesaler systems.”
Other companies that offer HRT products include Winona and MyAlloy, though these don’t offer testosterone products, according to Labourel.
Photo: akindo, Getty Images